Want to create an interactive transcript for this episode?
Podcast: Private Investor's Podcasts
Episode: PIP008 UK Share Review of Bioventix and The Incredible Profitability of Diagnostic Antibodies
Description: This time Maynard Paton and Roland Head discuss the investment potential of Bioventix (BVXP) and diagnostic antibodies. Both Maynard and Roland hold AIM-listed Bioventix with Maynard's 2016 purchase of Bioventix at £11 and the shares now representing 12% of his portfolio. Roland later in 2021. Maynard and Roland break down this incredibly profitable company which has operating margins of over 70% and has maintained those margins for over five years. They discuss the recent AGM attended by Maynard, how Bioventix generates cash, future pipeline, the financials, dividends and current risks to the value and share price of this A...